ESCMID weekly news 28.07.2020

28 July 2020: ESCMID Weekly News
Having trouble viewing this email? View in your browser.


28 July 2020

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,
ESCMID Executive Office.


31st ECCMID – New dates announced

New dates have been announced for the 31st ECCMID in Vienna, Austria.

The 31st ECCMID will now take place from Friday, 9 July – Monday, 12 July 2021.

This decision to hold ECCMID in the Summer, as opposed to the usual mid-Spring, is of course due to the ongoing COVID-19 situation, which continues to restrict movement and gatherings of people both in Europe and further abroad. It is the hope that these restrictions will be more likely to be relaxed at this time, due to the measures currently being taken to curb the spread of the virus.

As well as onsite participation, there will also be the option for online participation in the conference proceedings. Abstract submission will open in 11 January 2021 and will close on 24 February 2021. 

› Read more

ECCVID Abstract Submission – One week to go!

Don’t miss the opportunity to submit your abstract for the ESCMID Conference on Coronavirus Disease, taking place online from 23–25 September 2020.

The call will close on 3 August 2020!

See the ESCMID Website for the abstract submission guidelines and template.

› Read more

Call for ESCMID Ethics Advisory Committee members

ESCMID is accepting applications to become a member of the new Ethics Advisory Committee, a new independent ESCMID body meant to advise the Executive Committee (EC) and other ESCMID members on ethical issues that may arise. 

If you have experience in developing and evaluating conflict of interest policies and/or an expertise in code of ethics in the scientific and medical field as well as experience and sensitisation in ethical issues management, you are welcome to send your application until 31 August 2020.

To learn more about the committee and the application procedure, please visit ESCMID website.

› Read more


EMA communication: Veterinary Medicines Regulation Highlights - Issue 1

EMA is pleased to share the first edition of the Veterinary Medicines Regulation Highlights which includes an update on the preparations for the implementation of Regulation (EU) 2019/6.

For more information on veterinary medicines regulatory information, please click here.

› Read more


EMA communication: EMA starts review of dexamethasone for treating adults with COVID-19 requiring respiratory support

EMA is reviewing results from the RECOVERY study arm that involved the use of dexamethasone in the treatment of patients with COVID-19 admitted to hospital. This part of the study looked into the effects of adding dexamethasone to usual care in adults receiving invasive ventilation, those given oxygen (e.g. through a mask) or those receiving no oxygen. Invasive ventilation involves use of a machine to push air through a tube inserted into the patient’s airway.

The RECOVERY study recorded deaths during 28 days after starting dexamethasone treatment. Preliminary results indicate that, compared with usual care, dexamethasone:

  • reduced mortality by about 35% in patients on invasive mechanical ventilation;

  • reduced mortality by about 20% in patients receiving oxygen without invasive ventilation;

  • did not reduce death in patients who were not receiving oxygen therapy.

The review aims to provide an opinion on the results of the RECOVERY study and in particular the potential use of dexamethasone for the treatment of adults with COVID-19.

EMA will communicate further when the review is complete.

This press release and related content have been published here. Please check EMA’s dedicated webpage on COVID-19 for the latest updates.

› Read more


CMI highlight: Evolution of viral quasispecies during SARS-CoV-2 infection

The present study aimed to describe genomic diversity of SARS-CoV-2 by next generation sequencing (NGS) in a patient with longitudinal follow-up for SARS-CoV-2 infection.

Sequential samples collected in a patient infected by SARS-CoV-2 were analysed, showing that majority consensus sequences were identical in most of the samples (5/7) and differed with one synonymous mutation from the Wuhan reference sequence. 

Most of mutations were substitution variations and about half of them had moderate or high impact on gene expression. Viral variants also differed between lower and upper respiratory tract samples collected on the same day, suggesting independent sites of replication of SARS-CoV-2.

› Read more

ESCMID Executive Office
P.O. Box 214
4010 Basel
Phone +41 61 5080 173
Visit us on LinkedIn Visit us on YouTube

The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.